This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

IGF-1 and Bone Loss in Women With Anorexia Nervosa

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Anne Klibanski, MD, Massachusetts General Hospital
Information provided by (Responsible Party):
Anne Klibanski, MD, Massachusetts General Hospital Identifier:
First received: July 26, 2011
Last updated: July 11, 2017
Last verified: July 2017
Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in bone density). A significant decrease in bone density is called osteopenia or osteoporosis. Sometimes the loss of bone density can be severe enough to cause breaks and fractures of the bones. It is not known what causes the bones to thin in anorexia nervosa. Women who have this condition often have thin or weak bones that are more likely to break. They also have very low levels of a chemical called IGF-1 in their body. This chemical is very important for increasing bone growth in puberty and for maintaining healthy adult bones. The investigators would like to find out if giving rhIGF-1 followed by risedronate or risedronate alone can lead to an increase in bone formation, bone density, and bone strength in women with anorexia nervosa.

Condition Intervention
Anorexia Nervosa Osteopenia Osteoporosis Drug: rhIGF-1 Drug: Risedronate Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: IGF-1 and Bone Loss in Women With Anorexia Nervosa

Resource links provided by NLM:

Further study details as provided by Anne Klibanski, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • Bone Mineral Density [ Time Frame: 12 Months ]
    Sequential therapy with physiologic rhIGF-1 followed by a bisphosphonate will increase bone mineral density in women with AN more than a bisphosphonate alone or placebo

Secondary Outcome Measures:
  • Bone Microarchitecture and strength [ Time Frame: 12 Months ]
    A significant improvement in bone microarchitecture and strength at the spine, ultradistal radius and tibia over a 12 month period.

Estimated Enrollment: 200
Study Start Date: October 2011
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: October 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: rhIGF-1 followed by Risedronate
Sequential therapy with rhIGF-1 for 6 months followed by 6 months of risedronate 35mg
Drug: rhIGF-1
Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
Other Name: Increlex
Drug: Risedronate
Risedronate 35mg PO one time weekly
Other Name: Actonel
Active Comparator: Risedronate
Risedronate 35mg for 12 months
Drug: Risedronate
Risedronate 35mg PO one time weekly
Other Name: Actonel
Placebo Comparator: Placebo
Placebo for 12 months
Drug: Placebo
Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-45 years
  • AN defined by DSM-IV diagnostic criteria, including weight less than 85% of ideal body weight (restricting or binge/purge type, BMI 15-17.5) OR meet criteria for sub-threshold AN, i.e., all DSM-IV criteria except that patients can have a BMI of <18.5 kg/m2 with or without amenorrhea
  • Oral contraceptive use prior to enrollment
  • BMD T score < -1.0
  • Normal FSH and TSH or free T4
  • Normal serum 25-OH vitamin D (>20 ng/mL) and calcium levels
  • Ongoing care from a primary care provider
  • Agree to use barrier contraception

Exclusion Criteria:

  • Any subject with contraindications to risedronate
  • Any subject with binge-purge subtype of anorexia nervosa who vomits regularly as their form of purging (vs. those who use laxatives or diuretics) and who have significant periodontal disease, tooth erosion or an invasive dental or periodontal procedure within the previous three months.
  • Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's or renal failure
  • Any medication known to affect bone metabolism within 3 months of the study, excluding oral contraceptives. Bisphosphonates must have been discontinued for at least one year before participation
  • Serum potassium <3.0 meq/L
  • Serum ALT >3 times upper limit of normal
  • eGFR of less than 30 ml/min
  • Pregnant and/or breastfeeding
  • Diabetes mellitus
  • Active substance abuse, including alcohol
  • History of malignancy
  • Atraumatic fracture within the prior year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01406444

Contact: Erinne Meenaghan, NP 617-724-7393
Contact: Karen Miller, MD 617-726-3870

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Anne Klibanski, MD         
Sub-Investigator: Karen Miller, MD         
Sub-Investigator: Erinne Meenaghan, NP         
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Anne Klibanski, MD Massachusetts General Hospital
Study Chair: Erinne Meenaghan, NP Massachusetts General Hospital
Study Director: Karen Miller, MD Massachusetts General Hospital
  More Information

Responsible Party: Anne Klibanski, MD, Chief, Neuroendocrine Unit, Massachusetts General Hospital Identifier: NCT01406444     History of Changes
Other Study ID Numbers: 2R01DK052625 ( U.S. NIH Grant/Contract )
Study First Received: July 26, 2011
Last Updated: July 11, 2017

Keywords provided by Anne Klibanski, MD, Massachusetts General Hospital:
Anorexia Nervosa
Bone density

Additional relevant MeSH terms:
Anorexia Nervosa
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Feeding and Eating Disorders
Mental Disorders
Signs and Symptoms, Digestive
Signs and Symptoms
Risedronate Sodium
Etidronic Acid
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on September 21, 2017